Infographics
Patient Satisfaction and Experience with Risankizumab Body Injector in Adults with Crohn’s Disease
Maintenance Dosing Following Induction Response in Crohn’s Disease and Ulcerative Colitis
Effectiveness of Upadacitinib in Patients with Moderate to Severe Ulcerative Colitis
Real-World Clinical Effectiveness and Safety of Risankizumab in Patients with Crohn’s Disease: A Post-Marketing Prospective Non-Interventional Study
Upadacitinib showed sustained long-term improvements in quality of life, fatigue, and work productivity in moderate-to-severe Crohn’s disease.
Upadacitinib vs Advanced Therapies
Real-world analysis showed time to remission with upadacitinib compared with other advanced therapies in moderate-to-severe ulcerative colitis.
Upadacitinib demonstrated sustained long-term efficacy in patients with moderate-to-severe Crohn’s disease with prior biologic exposure.
Interim PROFUNDUS study results showed real-world effectiveness, symptom improvement, and safety of upadacitinib in moderate-to-severe ulcerative colitis.
Endoscopic Healing with Upadacitinib
Upadacitinib improved histologic and endoscopic-histologic outcomes in the colon and ileum of patients with moderate-to-severe Crohn’s disease.
Risankizumab After Ustekinumab Failure
Risankizumab demonstrated clinical and endoscopic improvements in patients with moderate-to-severe Crohn’s disease who previously failed ustekinumab.
Post hoc SEQUENCE study analysis showed durable efficacy of risankizumab through week 148 in patients with moderate-to-severe Crohn’s disease.
Three-year SEQUENCE study results showed long-term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn’s disease.
Interim COMMAND open-label extension results showed up to 3 years of efficacy and safety of risankizumab maintenance therapy in moderate-to-severe ulcerative colitis.
Interim U-ACCOMPLISH open-label extension results showed up to 5 years of efficacy and safety of upadacitinib in moderate-to-severe ulcerative colitis.
